FOXA1 in prostate cancer.
- Author:
Hui-Yu DONG
1
;
Lei DING
1
;
Tian-Ren ZHOU
1
;
Tao YAN
1
;
Jie LI
1
;
Chao LIANG
1
Author Information
- Publication Type:Journal Article
- Keywords: androgen receptor; forkhead box protein A1; mutation; prostate cancer
- MeSH: Humans; Male; Androgen Antagonists/therapeutic use*; Androgens/metabolism*; Hepatocyte Nuclear Factor 3-alpha/metabolism*; Mutation; Prostatic Neoplasms, Castration-Resistant/drug therapy*; Receptors, Androgen/metabolism*
- From: Asian Journal of Andrology 2023;25(3):287-295
- CountryChina
- Language:English
- Abstract: Most prostate cancers initially respond to androgen deprivation therapy (ADT). With the long-term application of ADT, localized prostate cancer will progress to castration-resistant prostate cancer (CRPC), metastatic CRPC (mCRPC), and neuroendocrine prostate cancer (NEPC), and the transcriptional network shifted. Forkhead box protein A1 (FOXA1) may play a key role in this process through multiple mechanisms. To better understand the role of FOXA1 in prostate cancer, we review the interplay among FOXA1-targeted genes, modulators of FOXA1, and FOXA1 with a particular emphasis on androgen receptor (AR) function. Furthermore, we discuss the distinct role of FOXA1 mutations in prostate cancer and clinical significance of FOXA1. We summarize possible regulation pathways of FOXA1 in different stages of prostate cancer. We focus on links between FOXA1 and AR, which may play different roles in various types of prostate cancer. Finally, we discuss FOXA1 mutation and its clinical significance in prostate cancer. FOXA1 regulates the development of prostate cancer through various pathways, and it could be a biomarker for mCRPC and NEPC. Future efforts need to focus on mechanisms underlying mutation of FOXA1 in advanced prostate cancer. We believe that FOXA1 would be a prognostic marker and therapeutic target in prostate cancer.
